Drug Trial Radar · NCT03567577
Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS
Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
92
Actual
Start
May 23, 2018
Primary completion
Dec 27, 2024
Study completion Dec 27, 2024
Sponsor
- Lead sponsor
- Apeptico Forschung und Entwicklung GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase IIb, randomized, placebo-controlled, double-blind, dose escalation study will assess the local and systemic safety of 7 days orally inhaled sequential multiple ascending doses of solnatide in patients with pulmonary permeability oedema and moderate-to-severe ARDS and review potential efficacy endpoints for a future phase III pivotal trial.
Conditions
- ARDS
Interventions
Solnatide 25 mg powder for reconstitution for solution for inhalationDrug
Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
0.9% Saline SolutionDrug
Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety endpoint: Any cause deathTime frame: Randomisation - day 28
- Safety endpoint: Drug-related adverse eventsTime frame: Randomisation - day 14
- Safety endpoint: All adverse eventsTime frame: Randomisation - day 28
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Univ. Klinik für Innere Medizin / Gem. Einrichtung für Intensiv- und Notfallmedizin/GE Medizinische Universität Innsbruck
Innsbruck, Austria
Department of Anesthesia, General Intensive Care and Pain Control,Medical University of Vienna
Vienna, State of Vienna, Austria
Univ.-klinik f. Herz-, Thorax-, Gefäßchirurgische Anästhesiologie und lntensivmedizin, Medizinische Universität Graz
Graz, Styria, Austria
Universitätsklinikum Bonn, Operative Intensivmedizin, Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin
Bonn, Germany
Georg-August-Universität Göttingen
Göttingen, Germany
Klinik für Anästhesiologie und operative Intensivmedizin, Universitätsklinikum Schleswig-Holstein, Campus Kiel,
Kiel, Germany
Klinik für Anästhesiologie / Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Germany
Klinik für Anästhesiologie und operative Intensivmedizin; Universitätsmedizin Mannheim
Mannheim, Germany
Klinik für Anästhesiologie und Intensivmedizin; Klinikum rechts der Isar der TU München
München, Germany
Klinik und Poliklinik für Innere Medizin II; Klinikum rechts der Isar der TU München
München, Germany
Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie; Universitätsklinikum Münster
Münster, Germany
Universitätsklinikum Würzburg, Klinik und Poliklinik für Anästhesiologie
Würzburg, Germany
Klinik für Anaesthesiologie, Klinikum der Universität München, Campus Großhadern
München, Bavaria, Germany
Klinik für Operative Intensivmedizin und Intermediate Care
Aachen, North Rhine-Westphalia, Germany
Klinik und Poliklinik für Anästhesiologie und Intensivtherapie / Universitätsklinikum Carl Gustav Carus
Dresden, Saxony, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.